Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial

Toshihiko Doi, Yukinori Kurokawa, Akira Sawaki, Yoshito Komatsu, Masato Ozaka, Tsuyoshi Takahashi, Yoichi Naito, Shuichi Ohkubo, Toshirou Nishida

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial'. Together they form a unique fingerprint.

Medicine & Life Sciences